BLACKSBURG, Va.--(BUSINESS WIRE)--Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland. Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.
